Novo Nordisk is dropping all its R&D activities into inflammatory disorders following the discontinuation of its lead anti-inflammatory product, anti-IL-20 for the treatment of rheumatoid arthritis, which it announced last month.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?